Historically, NASH drug development strategy has started in advanced fibrosis with the goal of progressing to cirrhosis next. This episode suggests an entirely different approach.
The episode starts by discussing the complexities of treating cirrhosis and evolves into a discussion on why compensated cirrhosis might be the BEST place to achieve fast, successful drug development today.
Key moments include:
10:12 – Why discuss cirrhosis?
11:40 – Challenges in cirrhosis treatment and drug development
13:08 – A changing viewpoint on cirrhosis as drug development target
17:24 – NASH and cirrhosis disease progression
20:10 – Diagnosing and stratifying cirrhosis patients
24:20 – NITs might make cirrhosis a better drug development target than F2/3
30:06 – Building momentum to reconsider NASH and cirrhosis drug development
33:47 – Identifying the conceptual road block in the move toward NITs in cirrhosis
39:09 – Formulating a plan of action to strengthen cirrhosis drug development and treatment
40:53 – A “disruptive technology” to pool clinical trial results
44:28 – The challenge: pushing cirrhosis treatment and drug development forward
50:09 – Business section